OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Cristea on Investigational Maintenance Strategies in Ovarian Cancer

July 2nd 2019

Mihaela C. Cristea, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses investigational maintenance strategies in advanced ovarian cancer.

Dr. Stinchcombe Discusses Differences in Toxicity Profiles Among ALK Inhibitors in NSCLC

July 2nd 2019

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the differences in toxicity profiles between brigatinib (Alunbrig) and alectinib (Alecensa) in ALK-positive non–small cell lung cancer (NSCLC).

Dr. Lieu on Investigational Immunotherapy Strategies in mCRC

July 2nd 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses investigational immunotherapy strategies in metastatic colorectal cancer (mCRC).

Dr. van Tilburg on Larotrectinib in TRK+ Pediatric Cancers

July 2nd 2019

Cornelis M. van Tilburg, MD, PhD, pediatric oncologist, Hopp Children’s Cancer Center Heidelberg, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive cancers who have brain metastases or primary central nervous system tumors.

Dr. Fertrin on the FDA Approval of Avatrombopag in ITP

July 2nd 2019

Kleber Y. Fertrin, MD, PhD, assistant professor, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the FDA approval of avatrombopag in immune thrombocytopenia (ITP).

Dr. Tiacci on Vemurafenib/Rituximab Combo in HCL

July 2nd 2019

Enrico Tiacci, MD, discusses safety and efficacy results of a trial evaluating the BRAF inhibitor vemurafenib combined with rituximab in hairy cell leukemia.

Dr. Lennes on Aspects of Lung Cancer Screening

June 28th 2019

Inga T. Lennes, MD, MBA, MPH, medical director, Ambulatory Services, director of clinical quality, Massachusetts General Hospital Cancer Center, discusses aspects of lung cancer screening.

Dr. Shadman on Challenges With CAR T-Cell Therapy

June 28th 2019

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, Department of Medicine, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses challenges with CAR T-cell therapy.

Dr. Choudhury on Targeted Therapy in Prostate Cancer

June 28th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the use of targeted therapy in prostate cancer.

Dr. Gutierrez on Biomarker-Directed Precision Oncology of Pembrolizumab-Based Combos in NSCLC

June 28th 2019

Martin E. Gutierrez, MD, discusses the biomarker-directed precision oncology of pembrolizumab-based combination therapy in the treatment of patients with non–small cell lung cancer.

Experts Highlight Ongoing Research Efforts Across Tumor Types

June 28th 2019

OncLive interviewed experts at the State of the Science Summits in June 2019 on research being conducted at their respective institutions.

Dr. McGregor on the Goal of the PRONOUNCE Trial in Prostate Cancer

June 28th 2019

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the hope for the phase IIb PRONOUNCE trial in prostate cancer.

Dr. Sehgal on the Structure and Manufacturing Process of CAR T Cells

June 28th 2019

Alison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.

Dr. Elhassadi on the Relationship Between p53 Expression and Prognosis in MCL

June 28th 2019

Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses p53 expression and prognosis in mantle cell lymphoma (MCL).

Dr. Paik on Tepotinib in METex14-Mutated NSCLC

June 27th 2019

Paul K. Paik, MD, discussed using tepotinib—a highly selective, ATP-competitive, reversible, potent MET TKI—to treat patients with non–small cell lung cancer with MET exon 14 skipping mutations.

Dr. Saba on Improving Cancer Detection Rates in HNSCC

June 27th 2019

Nabil F. Saba, MD, FACP, discussed the role of general practitioners in maintaining the health of their patients with cancer and how to better diagnosis select types of head and neck cancer.

Dr. Ready on Promising Treatment Approaches in SCLC

June 26th 2019

Neal E. Ready, MD, PhD, professor of medicine, Duke University School of Medicine, member, Duke Cancer Institute, discusses emerging treatment approaches in small cell lung cancer (SCLC).

Dr. Einstein on Treatment Approaches in Early Oligometastatic Prostate Cancer

June 26th 2019

David J. Einstein, MD, instructor of medicine, Harvard Medical School, attending physician, Beth Israel Deaconess Medical Center, discusses treatment approaches for patients with early evidence of oligometastatic prostate cancer.

Dr. Hochster on SWOG S1513 Results in Pancreatic Cancer

June 26th 2019

Howard Hochster, MD, FACP, discusses results from the SWOG S1513 study, which examined the use of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) versus solely FOLFIRI in metastatic pancreatic cancer.

Dr. Shah on Results of ZUMA-3 Study for ALL

June 26th 2019

Bijal Shah, MD, discusses the results of the phase I/II ZUMA-3 study, which looked at using KTE-X19, an anti-CD19 CAR T-cell therapy, to treat patients with relapsed/refractory acute lymphoblastic leukemia.